← Leaderboards
Amanda Malone
Auritec Pharmaceuticals, Inc.
$4,368,893
Attributed
$7,158,790
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2011–18$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,659,510 · 6
FDA$499,280 · 1
By mechanism
R44$4,145,128 · 2
U19$1,578,996 · 1
R43$935,386 · 3
U01$499,280 · 1
Top collaborators
- Thomas J. Smith9 shared
Most similar at Auritec Pharmaceuticals, Inc.
Same institution · by research overlap
- John A Moss$9,543,203
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsPharmaceutical PreparationsBaseSafetyPharmacologic SubstancePre-ClinicalEnvironmentDrug KineticsDrug Delivery SystemsDevicesSheepMarketingInvestigational New Drug ApplicationClinical TrialsProgramsDrug FormulationsDrug DevelopmentPreventChemistryPhase Iii Clinical TrialsProceduresInnovationResearch PersonnelSmall Business Innovation Research Grant
Grant awards (11)
Project 5: IND-enabling Critical Path Project: GMP Manufacture of a Combination I$1,078,750
U19 · FY2018 · AI · contact PI
Project 5: IND-enabling Critical Path Project: GMP Manufacture of a Combination I$500,246
U19 · FY2017 · AI · contact PI
Depot intra-articular fluticasone for the treatment of arthritis$628,279
R44 · FY2014 · AR
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$975,223
R44 · FY2013 · AI
Depot intra-articular fluticasone for the treatment of arthritis$563,622
R44 · FY2013 · AR
An IVIVC system to facilitate the development of a generic Vitrasert$499,280
U01 · FY2013 · FD
Microbicide intravaginal ring IND enabling studies$338,981
R43 · FY2013 · HD
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$978,004
R44 · FY2012 · AI
Intravaginal ring delivery of tenofovir and emtricitabine$300,000
R43 · FY2012 · AI
Sustained Release intravitreal VEGFR inhibition to prevent blindness$296,405
R43 · FY2012 · EY
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$1,000,000
R44 · FY2011 · AI